原发性硬化性胆管炎患者接受循环死亡后捐献肝移植的临床结局
本研究前瞻性评估2006至2016年因原发性硬化性胆管炎(PSC)接受肝移植的患者,按供体类型分为循环死亡后捐献(DCD)组35例与脑死亡后捐献(DBD)组108例。结果显示DCD组缺血型胆道病变发生率更高(4.4 vs 0例/100患者年,p<0.001),但移植肝丢失、患者死亡及胆道狭窄总体风险与DBD组无显著差异。作者认为在器官短缺时代,DCD供肝是PSC患者肝移植的可行选择。
要点
- PSC患者接受DCD与DBD肝移植后移植肝丢失和患者死亡率无显著差异。
- DCD组缺血型胆道病变发生率高于DBD组(4.4 vs 0例/100患者年,p<0.001)。
- 术后胆道狭窄总体风险在DCD与DBD组间无显著差异(HR 1.20,95%CI 0.58-2.46,p=0.624)。
核心结论
- PSC患者接受DCD供肝与DBD供肝移植相比,移植肝丢失和患者生存无显著差异。
- 在器官短缺时代,DCD供肝是PSC患者肝移植的可行治疗选择。
研究设计与样本
- 前瞻性评估2006至2016年因PSC接受肝移植的患者,按供体类型分层为DCD组35例与DBD组108例。
主要发现
- DCD组与DBD组手术时间、需重症监护支持天数、总机械通气天数、急性肾损伤发生率、需肾脏替代治疗(RRT)或总RRT天数均无显著差异。
- DCD组缺血型胆道病变发生率高于DBD组(4.4 vs 0例/100患者年,p<0.001)。
- DCD组与DBD组移植术后胆道狭窄总体风险无显著差异(HR 1.20,95%CI 0.58-2.46,p=0.624),吻合口狭窄或复发性PSC亚组分析亦无显著差异。
- DCD组与DBD组移植肝丢失发生率无显著差异(3.6 vs 3.1例/100患者年,p=0.34),患者死亡率无显著差异(3.9 vs 4.7例/100患者年,p=0.6)。
- DCD肝移植未增加移植肝丢失风险(HR 1.69,95%CI 0.58-4.95,p=0.341)或患者死亡风险(HR 0.75,95%CI 0.25-2.21,p=0.598)。
临床怎么用
- 作者认为,在器官短缺和等待名单时间延长的时代,DCD供肝是PSC患者肝移植的潜在治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIM: Primary sclerosing cholangitis (PSC) is a progressive fibro-inflammatory cholangiopathy for which liver transplantation is the only life-extending intervention. These patients may benefit from accepting liver donation after circulatory death (DCD), however their subsequent outcome is unknown. The aim of this study was to determine the clinical impact of using DCD liver grafts in patients specifically undergoing transplantation for PSC. METHODS: Clinical outcomes were prospectively evaluated in PSC patients undergoing transplantation from 2006 to 2016 stratified by donor type (DCD, n=35 vs. donation after brainstem death [DBD], n=108). RESULTS: In liver transplantation for PSC; operating time, days requiring critical care support, total ventilator days, incidence of acute kidney injury, need for renal replacement therapy (RRT) or total days requiring RRT were not significantly different between DCD vs. DBD recipients. Although the incidence of ischaemic-type biliary lesions was greater in the DCD group (incidence rate [IR]: 4.4 vs. 0 cases/100-patient-years; p<0.001) there was no increased risk of post-transplant biliary strictures overall (hazard ratio [HR]: 1.20, 0.58-2.46; p=0.624), or in sub-analysis specific to anastomotic strictures or recurrent PSC, between donor types. Graft loss and mortality rates were not significantly different following transplantation with DCD vs. DBD livers (IR: 3.6 vs. 3.1 cases/100-patient-years, p=0.34; and 3.9 vs. 4.7, p=0.6; respectively). DCD liver transplantation in PSC did not impart a heightened risk of graft loss (HR: 1.69, 0.58-4.95, p=0.341) or patient mortality (0.75, 0.25-2.21, p=0.598). CONCLUSION: Transplantation with DCD (vs. DBD) livers in PSC patients does not impact graft loss or patient survival. In an era of organ shortage, DCD grafts represent a viable therapeutic option for liver transplantation in PSC patients. Lay summary: This study examines the impact of liver transplantation in primary sclerosing cholangitis (PSC) with organs donated after circulatory death (DCD), compared to donation after brainstem death (DBD). We show that in appropriately selected patients, the outcomes for DCD transplantation mirror those using DBD livers, with no significant differences in complication rate, patient survival or transplanted liver survival. In an era of organ shortage and increasing wait-list times, DCD livers represent a potential treatment option for transplantation in PSC.
引用
- Trivedi PJ, Scalera I, Slaney E, et al. Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis. J Hepatol. 2017. PMID: 28690174. doi:10.1016/j.jhep.2017.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。